Kellie Combs, Ropes & Gray life sciences partner, analyzes three documents released by the FDA outlining the agency’s current thinking regarding drug and device manufacturers’ communication of information not contained in FDA-approved labeling.
Trending Similar Videos
China’s new cybersecurity law
Mimi Yang, a Ropes & Gray government enforcement partner in Hong Kong, provides an overview of China’s new cybersecurity law (CSL), which came into effect in June 2017.
Value-based health care: the role of payors
Bill Knowlton, Ropes & Gray health care partner, examines the critically important role of payors in value-based health care programs.
FTC's merger remedies study
Jonathan Klarfeld, Ropes & Gray antitrust partner, discusses key takeaways and likely impacts of the Federal Trade Commission's recent divestiture study.
Department of Labor's Fiduciary Rule
David Tittsworth, Ropes & Gray investment management counsel, analyzes the possible fate of the Department of Labor’s Fiduciary Rule.
Changing values of IP and data in deals
Ed Black, co-head of Ropes & Gray’s IP transactions and technology, media & telecommunications practice groups, discusses changing values of IP and data in M&A transactions.
Value-based health care: provider integration
John Chesley, Ropes & Gray health care partner, addresses developments for providers to consider as they integrate and move towards value-based health care models.